TVTX

Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products are Thiola and Thiola EC (tiopronin tablets) used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company has received approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II) and is a non-immunosuppressive therapy approved for the treatment of this condition. FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA). Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN in the United States and Europe.